Fuji Pharma Lifts Interim Dividend Forecast on Solid Core Product Sales

Fuji Pharma Co., Ltd. ( (JP:4554) ) has provided an announcement.

Fuji Pharma Co., Ltd. has revised its interim dividend forecast for the fiscal year ending September 2026 after confirming that sales of its main products are generally progressing smoothly and that its financial position remains sound. The company, which targets a 30% dividend payout ratio based on operating profit and follows a progressive dividend policy, will raise its second-quarter dividend forecast from ¥21.00 to ¥23.00 per share, lifting the projected annual dividend from ¥47.00 to ¥49.00, compared with ¥45.50 in the previous fiscal year, signaling a modest enhancement of shareholder returns.

The board’s decision to increase the interim payout reflects management’s confidence in current business performance and supports Fuji Pharma’s stance on stable, continuous shareholder remuneration. For investors, the higher dividend underscores the contribution of core products to earnings and suggests that, barring unforeseen factors, the company is prepared to share incremental operating gains through improved cash returns while sustaining a disciplined capital policy.

The most recent analyst rating on (JP:4554) stock is a Buy with a Yen2651.00 price target. To see the full list of analyst forecasts on Fuji Pharma Co., Ltd. stock, see the JP:4554 Stock Forecast page.

More about Fuji Pharma Co., Ltd.

Fuji Pharma Co., Ltd. is a Japan-based pharmaceutical company that develops and sells prescription medicines, with a focus on key branded products that underpin its earnings. The company emphasizes stable, ongoing shareholder returns and manages dividends based on operating profit while maintaining financial soundness.

Average Trading Volume: 164,401

Technical Sentiment Signal: Buy

Current Market Cap: Yen55.27B

Find detailed analytics on 4554 stock on TipRanks’ Stock Analysis page.